血清CA72-4在消化系癌症中的临床应用  

Clinical significance of serum CA72-4 in patients with digestive system cancers

作　　者：张桂芬[1] 邓为民[1] 

机构地区：[1]天津医科大学基础医学院免疫学系 天津市细胞与分子免疫学重点实验室 教育部免疫微环境与疾病重点实验室,天津市300070

出　　处：《世界华人消化杂志》2015年第5期862-865,共4页World Chinese Journal of Digestology

摘　　要：目的:探讨血清肿瘤标志物糖类抗原72-4(carbohydrate antigen 72-4,CA72-4)在消化系癌症中的应用意义和临床价值.方法:采用电化学发光法分别测定310例消化系癌症患者(肝癌52例,食管癌36例,胰腺癌50例,胆道癌35例,胃癌74例,肠癌63例)及50例对照组消化系良性病变患者的血清CA72-4水平.结果:CA72-4在肝癌组阳性率为21.15%,食管癌组27.78%,胰腺癌组36.00%,胆道癌组37.14%,胃癌组51.35%,肠癌组61.90%.各消化系癌症组血清CA72-4水平均显著高于对照组,差异有统计学意义.结论:血清CA72-4在消化系癌症中有较高的阳性率,尤其是胃癌和肠癌,同时对鉴别消化系良恶性肿瘤有重要的价值,应加大临床的推广应用.AIM：To investigate the clinical significance of serum carbohydrate antigen 72-4（CA72-4） in patients with digestive system cancers.METHODS：Serum CA72-4 levels were determined in 310 patients with digestive system cancers（including 52 with liver cancer,36 with esophageal cancer,50 with pancreatic cancer,35 with bile duct carcinoma,74 with gastric cancer and 63 with colon cancer） and 50 patients with benign lesions by electrochemiluminescence immunoassay.RESULTS：The positive rate of CA72-4 was21.15%in the liver cancer group,27.78%in the esophageal cancer group,36.00%in the pancreatic cancer group,37.14%in the bile duct carcinoma group,51.35%in the gastric cancer group,and 61.90%in the colorectal cancer group.The levels of serum CA72-4 in digestive system cancer patients were significantly higher than those in patients with benign lesions.CONCLUSION：Serum CA72-4 has a higher positive rate in patients with digestive system cancers,especially in those with gastric cancer and colon cancer,and it has important value to differentiate benign and malignancy digestive tumors.

关 键 词：消化系癌症 肿瘤标志物 糖类抗原72-4 胃癌 肠癌 胰腺癌 

分 类 号：R735[医药卫生—肿瘤]